collection
https://read.qxmd.com/read/23714310/drug-induced-immune-thrombocytopenia
#21
REVIEW
Beng H Chong, Philip Young-Ill Choi, Levon Khachigian, Jose Perdomo
Thrombocytopenia is caused by immune reactions elicited by diverse drugs in clinical practice. The activity of the drug-dependent antibodies produces a marked decrease in blood platelets and a risk of serious bleeding. Understanding of the cellular mechanisms that drive drug-induced thrombocytopenia has advanced recently but there is still a need for improved laboratory tests and treatment options. This article provides an overview of the different types of drug-induced thrombocytopenia, discusses potential pathologic mechanisms, and considers diagnostic methods and treatment options...
June 2013: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/23518804/tumor-necrosis-factor-%C3%AE-antagonist-associated-psoriasis-in-inflammatory-diseases-an-analysis-of-the-fda-adverse-event-reporting-system
#22
COMPARATIVE STUDY
Kevin E Kip, Jason M Swoger, Lisa M Grandinetti, Arthur M Barrie, Julia B Greer, Miguel D Regueiro
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory, relapsing, and progressive condition that leads to bowel damage and subsequent stricturing or penetrating complications. Tumor necrosis factor (TNF) α antagonists (e.g., infliximab) can achieve sustained remission in CD. However, a paradox exists as to whether use of these medications, which effectively treat psoriasis, also confer risk of developing psoriasiform lesions. METHODS: Data from the Food and Drug Administration Adverse Event Reporting System (2004-2011) were analyzed...
May 2013: Inflammatory Bowel Diseases
https://read.qxmd.com/read/23474780/skin-side-effects-of-inflammatory-bowel-disease-therapy
#23
REVIEW
Joana Torres, Sébastien Buche, Emmanuel Delaporte, Jean-Frédéric Colombel
Skin manifestations are common in patients suffering from inflammatory bowel disease (IBD) and can be associated with the disease itself, with nutritional deficiencies, or with therapy. All drugs currently used for treating IBD have the potential to cause dermatologic manifestations that can have a wide range of clinical presentations, from mild drug eruptions to potentially life-threatening immune-mediated reactions. The wider use of thiopurines and anti-tumor necrosis factor in the past years has led to the recognition of 2 more skin complications of IBD therapy: the potentially disfiguring non-melanoma skin cancer associated with the current or past use of thiopurines and the paradoxical new onset or exacerbation of anti-tumor necrosis factor-associated psoriasis...
April 2013: Inflammatory Bowel Diseases
https://read.qxmd.com/read/23453887/dermatological-adverse-reactions-during-anti-tnf-treatments-focus-on-inflammatory-bowel-disease
#24
REVIEW
Giammarco Mocci, Manuela Marzo, Alfredo Papa, Alessandro Armuzzi, Luisa Guidi
The clinical introduction of tumour necrosis factor (TNF) inhibitors has deeply changed the treatment of inflammatory bowel diseases (IBD). It has demonstrated impressive efficacy as compared to alternative treatments, allowing for the chance to achieve near-remission and long-term improvement in function and quality of life and to alter the natural history of Crohn's disease (CD) and ulcerative colitis (UC). As a consequence of longer follow-up periods the number of side effects which may be attributed to treatment with biologics is growing significantly...
November 2013: Journal of Crohn's & Colitis
https://read.qxmd.com/read/23274341/infliximab-induced-psoriasis-and-psoriasiform-skin-lesions-in-pediatric-crohn-disease-and-a-potential-association-with-il-23-receptor-polymorphisms
#25
JOURNAL ARTICLE
Mary E Sherlock, Thomas Walters, Merit M Tabbers, Karen Frost, Mary Zachos, Aleixo Muise, Elena Pope, Anne M Griffiths
BACKGROUND: Infliximab (IFX), an established therapy for pediatric Crohn disease (CD), is also efficacious in treating psoriasis, a skin disorder, in which tumor necrosis factor-α is implicated pathogenically. Paradoxically, there have been numerous reports of new-onset psoriasis following tumor necrosis factor-α antagonist therapy in adult patients with inflammatory bowel disease, but pediatric data are sparse. METHODS: A retrospective review of all IFX-treated patients with CD, who subsequently developed psoriasis, at a single pediatric inflammatory bowel disease center, was performed...
May 2013: Journal of Pediatric Gastroenterology and Nutrition
https://read.qxmd.com/read/23265148/onset-of-psoriasis-in-patients-with-inflammatory-bowel-disease-treated-with-anti-tnf-agents
#26
REVIEW
Iván Guerra, Javier P Gisbert
Anti-TNF agents are widely used in the treatment of some inflammatory diseases, such as inflammatory bowel disease and psoriasis. Their use has led to a significant advance in the treatment of these diseases. Paradoxically, the onset of psoriatic lesions has been observed in patients on anti-TNF treatment. The cause of this side effect has not yet been clearly identified. In recent years, an increasing number of cases of psoriasis related to anti-TNF therapy in inflammatory bowel disease patients have been reported...
January 2013: Expert Review of Gastroenterology & Hepatology
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.